- Conditions
- Infections, Papillomavirus
- Interventions
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 346 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 39
- States / cities
- San Diego, California • San Francisco, California • Denver, Colorado + 34 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Appendix Adenocarcinoma, Human Papillomavirus-Related Anal Squamous Cell Carcinoma, Human Papillomavirus-Related Cervical Squamous Cell Carcinoma, Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis, Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma, Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Merkel Cell Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Peritoneal Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Stage III Merkel Cell Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7, Stage III Pleural Malignant Mesothelioma AJCC v7, Stage IV Merkel Cell Carcinoma AJCC v7, Stage IV Nasopharyngeal Carcinoma AJCC v7, Stage IV Pleural Malignant Mesothelioma AJCC v7, Stage IVA Nasopharyngeal Carcinoma AJCC v7, Stage IVB Nasopharyngeal Carcinoma AJCC v7, Stage IVC Nasopharyngeal Carcinoma AJCC v7, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Interventions
- Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Oropharynx, Human Papillomavirus Viruses, Drug Therapy, Cancer Vaccine
- Interventions
- Docetaxel, Cisplatin, PRGN-2009
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Human Papilloma Virus
- Interventions
- Zinc Sulfate, Placebo (Gelatin Tablet)
- Dietary Supplement · Other
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 21 Years to 65 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Head and Neck Cancer, Human Papilloma Virus
- Interventions
- MEDI0457, CELLECTRA®5P device, Durvalumab
- Drug · Device
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 14
- States / cities
- San Francisco, California • Orlando, Florida • Atlanta, Georgia + 10 more
- Conditions
- Human Papilloma Virus (HPV)
- Interventions
- Text Message, PostCard, Standard of Care, Motivational Interview
- Behavioral
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Papillomavirus Infections
- Interventions
- 851B
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Enterprise, Alabama • Huntsville, Alabama + 85 more
- Conditions
- HPV - Anogenital Human Papilloma Virus Infection
- Interventions
- Menstrual Blood Analysis (Menstrual Blood Analysis)
- Diagnostic Test
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Healthy Subject, Human Papillomavirus Infection
- Interventions
- carrageenan-containing gel, Placebo, Laboratory Biomarker Analysis, Questionnaire Administration
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 19 Years to 35 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Newark, New Jersey
- Conditions
- Human Papilloma Virus Infection Type 16, Human Papilloma Virus Infection Type 18, Human Papilloma Virus
- Interventions
- Teal Health Self-Collection Device Group
- Device
- Lead sponsor
- Teal Health, Inc.
- Industry
- Eligibility
- 25 Years to 65 Years · Female only
- Enrollment
- 235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Portola Valley, California • Aurora, Colorado • Baton Rouge, Louisiana + 3 more
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation, FGFR3 Gene Mutation, Head and Neck Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Head and Neck Carcinoma, Recurrent Nasopharynx Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma
- Interventions
- BGJ398
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
- Interventions
- Tumor and HLA Profiling
- Diagnostic Test
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
- Conditions
- Squamous Cell Carcinoma of the Oropharynx, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- 44 doses of radiation, 54 doses of radiation
- Radiation
- Lead sponsor
- Indiana University
- Other
- Eligibility
- Not listed
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Cervical Neoplasia
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 21 Years to 100 Years · Female only
- Enrollment
- 131,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Infections, Papillomavirus, Papillomavirus Vaccines
- Interventions
- CervarixTM, HPV investigational vaccine GSK568893A, different formulations
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 25 Years · Female only
- Enrollment
- 383 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Golden, Colorado • Salt Lake City, Utah
- Conditions
- Human Papillomavirus Vaccines
- Interventions
- Community Pharmacists Vaccinating Against Cancer
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Mesa, Arizona
- Conditions
- Human Papillomavirus-Related Carcinoma, Human Papillomavirus Positive Oropharyngeal Carcinoma, Human Papillomavirus Positive Cervical Carcinoma, Human Papillomavirus Positive Anal Carcinoma, Human Papillomavirus Positive Vulvar Carcinoma, Human Papillomavirus Positive Penile Carcinoma
- Interventions
- HPV Specific T Cells, Cytoxan, Fludarabine, Nivolumab
- Genetic · Drug · Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cervical Cancer
- Interventions
- Multimodal optical imaging
- Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 25 Years to 49 Years · Female only
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Human Papillomavirus Infection
- Interventions
- Compliance, Message sidedness
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 11 Years to 15 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Galveston, Texas
- Conditions
- Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
- Interventions
- Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy
- Drug · Procedure
- Lead sponsor
- Emory University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
- Conditions
- Vulvar High Grade Squamous Intraepithelial Lesion (HSIL), Vulvar Dysplasia, Vulvar Intraepithelial Neoplasia (VIN), VIN2, VIN3, Pre-cancerous Lesions of the Vulva, Human Papillomavirus (HPV)
- Interventions
- VGX-3100, Imiquimod 5% Cream, CELLECTRA™ 2000
- Biological · Drug · Device
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 15
- States / cities
- Newark, Delaware • Augusta, Georgia • Chicago, Illinois + 12 more
- Conditions
- Influenza Vaccine, Papillomavirus Infection, Pertussis
- Interventions
- Vaccination Program
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 12 Years to 26 Years · Female only
- Enrollment
- 3,988 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 4
- States / cities
- Burlington, North Carolina • Durham, North Carolina • Raleigh, North Carolina
- Conditions
- Oropharynx Cancer
- Interventions
- Radiation Therapy
- Radiation
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia